3-氯水杨酸 | 1829-32-9

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯水杨酸
• 中文别名: 3-氯水扬酸；2-羟基-3-氯苯甲酸；3-氯-2-羟基苯甲酸
• 英文名称: 3-Chloro-2-hydroxybenzoic acid
• 英文别名: 3-Chlorosalicylic acid
• CAS: 1829-32-9
• 化学式: C₇H₅ClO₃
• mdl: MFCD00010390
• 分子量: 172.568
• InChiKey: PPINMMULCRBDOS-UHFFFAOYSA-N

物化性质

• 熔点：
  184-186 °C(lit.)
• 沸点：
  291.7±25.0 °C(Predicted)
• 密度：
  0.863 g/cm3
• 溶解度：
  DMSO（少量）、甲醇（少量）
• 保留指数：
  1548
• 稳定性/保质期：

  常温常压下稳定，应避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2918290000
• 安全说明：
  S26,S36
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  请将产品存放在密闭、通风且干燥的地方保存。

SDS

Name:	3-Chlorosalicylic Acid 98% Material Safety Data Sheet
Synonym:	None Known
CAS:	1829-32-9

Section 1 - Chemical Product MSDS Name:3-Chlorosalicylic Acid 98% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1829-32-9	3-Chlorosalicylic Acid	98.0	217-379-5

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1829-32-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: tan
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 184 - 186 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: Slightly soluble.
Specific Gravity/Density:
Molecular Formula: C7H5ClO3
Molecular Weight: 172.4862

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1829-32-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Chlorosalicylic Acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 1829-32-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1829-32-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1829-32-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氯水杨酸 生成 邻氯苯酚
  参考文献：
  名称：

  Tischtschenko, Zhurnal Russkago Fiziko-Khimicheskago Obshchestva, 1928, vol. 60, p. 161

  摘要：

  DOI：
• 作为产物：
  描述：

  2,3-二氯苯甲酸 在 吡啶 、 铜 、 potassium carbonate 作用下， 以 水 为溶剂， 反应 2.0h， 以85%的产率得到3-氯水杨酸
  参考文献：
  名称：

  以水为溶剂由相应的 2-氯苯甲酸合成水杨酸衍生物

  摘要：

  摘要 在吡啶作为助催化剂存在下，使用 Ullmann-Goldberg 反应条件可以实现以水为溶剂的改进的水杨酸合成。以良好的收率制备了许多水杨酸。

  DOI：

  10.1081/scc-120004857
• 作为试剂：
  描述：

  (2E,6E)-8-bromo-3,7-dimethylocta-2,6-dienyl acetate 在 叔丁基过氧化氢 、 selenium(IV) oxide 、 3-氯水杨酸 、 sodium hydride 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 46.0h， 生成 (2E,6E,10E,14E)-16-hydroxy-3,7,11,15-tetramethyl-9-(toluene-4-sulfonyl)hexadeca-2,6,10,14-tetraenyl acetate 、 (2E,6E,10E)-3,7,11,15-tetramethyl-9-(toluene-4-sulfonyl)hexadeca-2,6,10,14-tetraenyl acetate
  参考文献：
  名称：

  A convergent stereocontrolled synthesis of [3-¹⁴C]solanesol

  摘要：

  在这项通讯中，我们报告了合成约5 mCi的[3-14C]solanesol（1），其是通过四个步骤由乙基[3-14C]乙酰乙酸酯和（全-E）-八烯基溴化物（2）制备而成，特定放射性为19.83 mCi/mmol，化学/立体化学和放射化学纯度≥95%（见图1）。链的3位被选择为14C标记位点，因为该位置具有代谢稳定性。此次研究所需的未标记（全-E）-八烯基（18）（见方案4）是通过一种收敛的迭代“烯丙基-烯丙基”偶联方法，从易于获得的廉价起始材料派生的前体合成的。1 版权所有 © 2013 John Wiley & Sons, Ltd.

  DOI：

  10.1002/jlcr.3083

文献信息

• Carboxylation of Phenols with CO₂at Atmospheric Pressure
  作者：Junfei Luo、Sara Preciado、Pan Xie、Igor Larrosa

  DOI：10.1002/chem.201601114

  日期：2016.5.10

  A convenient and efficient method for the ortho‐carboxylation of phenols under atmospheric CO2 pressure has been developed. This method provides an alternative to the previously reported Kolbe–Schmitt method, which requires very high pressures of CO2. The addition of a trisubstituted phenol has proved essential for the successful carboxylation of phenols with CO2 at standard atmospheric pressure, allowing

  已经开发了一种在大气CO 2压力下使酚进行邻羧基羧化的便捷有效方法。该方法提供了以前报道的Kolbe-Schmitt方法的替代方法，后者需要非常高的CO 2压力。已证明添加三取代的苯酚对于在标准大气压下成功地将苯酚与CO 2羧化至关重要，从而可以有效制备各种水杨酸。
• [EN] KCNT1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE KCNT1 ET PROCÉDÉS D'UTILISATION
  申请人：PRAXIS PREC MEDICINES INC

  公开号：WO2020227097A1

  公开（公告）日：2020-11-12

  The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

  本发明部分涉及用于预防和/或治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或症状，以及基因中的功能增强突变（例如，KCNT1）的化合物和组合物。本文还提供了治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或症状，以及基因中的功能增强突变（如KCNT1）的方法。
• [EN] 5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE 5-SULFAMOYL-2-HYDROXYBENZAMIDE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017153952A1

  公开（公告）日：2017-09-14

  The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代水杨酰胺衍生物。具体而言，本发明涉及根据公式(I)的化合物：其中R、R1和R2如本文所述，或其药用可接受的盐。本发明的化合物是CD73的抑制剂，可用于治疗癌症、前癌症综合症以及与CD73抑制相关的疾病，例如艾滋病、治疗HIV、自身免疫疾病、感染、动脉粥样硬化和缺血再灌注损伤。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制CD73活性和治疗与之相关的疾病的方法。
• [EN] TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF<br/>[FR] INHIBITEURS TRICYCLIQUES DE L'INTERACTION PROTÉINE-PROTÉINE DU DOMAINE BTB DE BCL6 ET UTILISATIONS ASSOCIÉES
  申请人：ONTARIO INSTITUTE FOR CANCER RES OICR

  公开号：WO2019119145A1

  公开（公告）日：2019-06-27

  The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

  本申请涉及式(I)的化合物或其药用可接受的盐、溶剂化合物和/或前药，包括含有这些化合物或其药用可接受的盐、溶剂化合物和/或前药的组合物，以及在治疗可通过抑制与BCL6 BTB的相互作用可治疗的疾病、紊乱或状况中的各种用途，如癌症。
• Antibacterial Agents
  申请人：Aldrich Courtney

  公开号：US20080293666A1

  公开（公告）日：2008-11-27

  The invention provides compounds of formula (I) and salts thereof: R 1 -L-R 2 —B wherein R 1 , L, R 2 , and B have any of the values defined herein, as well as compositions comprising such compounds, and therapeutic methods comprising the administration of such compounds or salts. The compounds block siderophore production in bacteria and are useful as antibacterial agents.

  这项发明提供了化合物的公式(I)及其盐：R1-L-R2—B，其中R1、L、R2和B具有本文中定义的任何值，以及包含这种化合物的组合物，以及包含这种化合物或盐的治疗方法。这些化合物可以阻断细菌中的铁载体产生，并可用作抗菌剂。

表征谱图